Ultragenyx - Asset Resilience Ratio
Ultragenyx (RARE) has an Asset Resilience Ratio of 18.36% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Also explore Ultragenyx balance sheet assets for the complete picture of this company's asset base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2025)
This chart shows how Ultragenyx's Asset Resilience Ratio has changed over time. See Ultragenyx balance sheet quality to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Ultragenyx's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Ultragenyx worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $238.00 Million | 18.36% |
| Total Liquid Assets | $238.00 Million | 18.36% |
Asset Resilience Insights
- Good Liquidity Position: Ultragenyx maintains a healthy 18.36% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Ultragenyx Industry Peers by Asset Resilience Ratio
Compare Ultragenyx's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Royalty Pharma Plc
NASDAQ:RPRX |
Biotechnology | 0.11% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
|
Hyundai Bioscience Co. Ltd
KQ:048410 |
Biotechnology | 13.57% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 82.25% |
|
Lifecome Biochemistry Co Ltd
SHE:002868 |
Biotechnology | 4.69% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
Annual Asset Resilience Ratio for Ultragenyx (2013–2025)
The table below shows the annual Asset Resilience Ratio data for Ultragenyx.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 16.91% | $259.00 Million | $1.53 Billion | -12.11pp |
| 2024-12-31 | 29.02% | $436.30 Million | $1.50 Billion | +4.63pp |
| 2023-12-31 | 24.39% | $363.62 Million | $1.49 Billion | -15.39pp |
| 2022-12-31 | 39.78% | $614.82 Million | $1.55 Billion | +11.37pp |
| 2021-12-31 | 28.42% | $432.61 Million | $1.52 Billion | +0.68pp |
| 2020-12-31 | 27.73% | $488.01 Million | $1.76 Billion | -0.59pp |
| 2019-12-31 | 28.33% | $321.65 Million | $1.14 Billion | -19.80pp |
| 2018-12-31 | 48.12% | $346.27 Million | $719.56 Million | +20.82pp |
| 2017-12-31 | 27.31% | $134.00 Million | $490.75 Million | -13.21pp |
| 2016-12-31 | 40.51% | $219.03 Million | $540.63 Million | -20.86pp |
| 2015-12-31 | 61.37% | $343.43 Million | $559.57 Million | -21.05pp |
| 2014-12-31 | 82.42% | $163.16 Million | $197.97 Million | +5.39pp |
| 2013-12-31 | 77.03% | $45.95 Million | $59.65 Million | -- |
About Ultragenyx
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth fac… Read more